Protocol Ledger

NCT05991388 · Phase II/III · RECRUITING

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Interventional Phase II/III clinical trial protocol NCT05991388 sponsored by University of Birmingham in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-05-02 Enrollment: 210 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05991388
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)210 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05991388
Protocol FieldVerified Registry Value
NCT IdentifierNCT05991388
Consolidated Lead SponsorUniversity of Birmingham
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment210 participants (ESTIMATED)
Registered Start Date2024-05-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05991388
Hospital Research SiteLocationSite Profile
UZ LeuvenLeuven, BelgiumOpen Hospital Dossier ->
Sahlgrenska University hospitalGothenburg, SwedenOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI